TY - JOUR
T1 - Exposure to anesthesia is not associated with development of α-synucleinopathies
T2 - A nested case-control study
AU - Laporta, Mariana L.
AU - Kruthiventi, S. Chandralekha
AU - Stang, Cole D.
AU - Camerucci, Emanuele
AU - Martin, David P.
AU - Weingarten, Toby N.
AU - Hanson, Andrew C.
AU - Schroeder, Darrell R.
AU - Warner, David O.
AU - Savica, Rodolfo
AU - Sprung, Juraj
N1 - Funding Information:
Dr Savica receives research support from the National Institute on Aging , the National Institute of Neurological Disorders and Stroke , the Mayo Clinic Small Grants Program , the National Center for Advancing Translational Sciences (NCATS) , and an unrestricted grant from Acadia Pharmaceuticals, Inc . Dr Weingarten currently serves as a consultant to Medtronic in the role of chairman of the Clinical Endpoint Committee for the Prodigy Trial; he has received research support from Respiratory Motion and unrestricted investigator-initiated grants from Merck. All other authors have no financial or personal relationships to disclose. The authors declare that they have no conflicts of interest.
Funding Information:
The REP supported this work ( R01 AG034676 , PIs: WA Rocca and J St. Sauver) and the Mayo Clinic Center for Clinical and Translational Science (CTSA) , grant number UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS) .
Funding Information:
The REP supported this work (R01 AG034676, PIs: WA Rocca and J St. Sauver) and the Mayo Clinic Center for Clinical and Translational Science (CTSA), grant number UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS).Dr Savica receives research support from the National Institute on Aging, the National Institute of Neurological Disorders and Stroke, the Mayo Clinic Small Grants Program, the National Center for Advancing Translational Sciences (NCATS), and an unrestricted grant from Acadia Pharmaceuticals, Inc. Dr Weingarten currently serves as a consultant to Medtronic in the role of chairman of the Clinical Endpoint Committee for the Prodigy Trial; he has received research support from Respiratory Motion and unrestricted investigator-initiated grants from Merck. All other authors have no financial or personal relationships to disclose. The authors declare that they have no conflicts of interest.
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/7
Y1 - 2021/7
N2 - Introduction: Preclinical studies suggest that inhalational anesthetics may induce neuropathology changes in the nigrostriatal system, leading to development of α-synucleinopathies. We explored the role of general anesthesia in the development of Parkinson disease (PD) and other α-synucleinopathies. Methods: All α-synucleinopathy cases in Olmsted County, Minnesota, from January 1991, to December 2010, were identified from diagnostic codes, and then reviewed for type and index date of diagnosis. Cases were matched by sex and age (±1 year) to a referent control, a resident living in Olmsted County, and free of α-synucleinopathies before the index date (year of onset of the α-synucleinopathy). Medical records of both cases and controls were reviewed for lifetime exposure to anesthesia prior to the index date. Results: A total of 431 cases with clinically defined α-synucleinopathies were identified. Of these, 321 (74%) underwent 1,069 procedures under anesthesia before the diagnosis date, and in the control group, 341 (79%) underwent 986 procedures. When assessed as a dichotomous variable, anesthetic exposure was not significantly associated with α-synucleinopathies (odds ratio [OR], 0.75; 95% CI, 0.54-1.05; P=.094). No association was observed when anesthetic exposure was quantified by the number of exposures (OR, 0.64, 0.89, and 0.74, for 1, 2–3, and ≥4 exposures, respectively, compared to no exposure as the reference; P=.137) or quantified by the cumulative duration of exposure assessed as a continuous variable (OR, 1.00; 95% CI, 0.97-1.02 per 1-h increase of anesthetic exposure; P=.776). Conclusions: We did not observe a significant association between exposure to general anesthesia and risk for the development of α-synucleinopathies.
AB - Introduction: Preclinical studies suggest that inhalational anesthetics may induce neuropathology changes in the nigrostriatal system, leading to development of α-synucleinopathies. We explored the role of general anesthesia in the development of Parkinson disease (PD) and other α-synucleinopathies. Methods: All α-synucleinopathy cases in Olmsted County, Minnesota, from January 1991, to December 2010, were identified from diagnostic codes, and then reviewed for type and index date of diagnosis. Cases were matched by sex and age (±1 year) to a referent control, a resident living in Olmsted County, and free of α-synucleinopathies before the index date (year of onset of the α-synucleinopathy). Medical records of both cases and controls were reviewed for lifetime exposure to anesthesia prior to the index date. Results: A total of 431 cases with clinically defined α-synucleinopathies were identified. Of these, 321 (74%) underwent 1,069 procedures under anesthesia before the diagnosis date, and in the control group, 341 (79%) underwent 986 procedures. When assessed as a dichotomous variable, anesthetic exposure was not significantly associated with α-synucleinopathies (odds ratio [OR], 0.75; 95% CI, 0.54-1.05; P=.094). No association was observed when anesthetic exposure was quantified by the number of exposures (OR, 0.64, 0.89, and 0.74, for 1, 2–3, and ≥4 exposures, respectively, compared to no exposure as the reference; P=.137) or quantified by the cumulative duration of exposure assessed as a continuous variable (OR, 1.00; 95% CI, 0.97-1.02 per 1-h increase of anesthetic exposure; P=.776). Conclusions: We did not observe a significant association between exposure to general anesthesia and risk for the development of α-synucleinopathies.
KW - Halogenated anesthetics
KW - Lewy body dementia
KW - Parkinson disease
KW - Parkinson disease dementia
KW - α-synucleinopathies
UR - http://www.scopus.com/inward/record.url?scp=85108080493&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108080493&partnerID=8YFLogxK
U2 - 10.1016/j.parkreldis.2021.06.001
DO - 10.1016/j.parkreldis.2021.06.001
M3 - Article
C2 - 34147949
AN - SCOPUS:85108080493
SN - 1353-8020
VL - 88
SP - 76
EP - 81
JO - Parkinsonism and Related Disorders
JF - Parkinsonism and Related Disorders
ER -